Serum HER-2/NEU decline predicts improved response to trastuzumab-based therapy (serum HER-2/NEU study group)

被引：0
|
作者：
Ali, S. M.
Esteva, F. J.
Fornier, M.
Harris, L.
Kostler, W. J.
Lotz, J. P.
Luftner, D.
Pichon, M. F.
Tse, C.
Lipton, A.
机构：
[1] Penn State Univ, Milton S Hershey Med Ctr, Lebanon VA Med Ctr, Lebanon, PA USA
[2] MD Anderson Canc Ctr, Houston, TX USA
[3] Mem Sloan Kettering Canc Ctr, Dept Oncol, New York, NY 10021 USA
[4] Yale Univ, New Haven, CT USA
[5] Univ Hosp Vienna, Div Oncol, Vienna, Austria
[6] Tenon Hosp, Med Oncol Serv, Paris, France
[7] Humboldt Univ, Berlin, Germany
[8] Rene Huguenin Canc Ctr, Paris, France
[9] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：69 / 69
页数：1
相关论文
共 50 条
  • [1] Decline in serum HER-2/neu predicts response to trastuzumab-based therapy
    Ali, S. M.
    Brault, D.
    Brown-Shimer, S.
    Carney, W.
    Esteva, F. J.
    Fornier, M.
    Gligorov, J.
    Hamer, P.
    Harris, L.
    Kostler, W. J.
    Leitzel, K.
    Lotz, J. P.
    Luftner, D.
    Pichon, M. F.
    Thiel, R. P.
    Tse, C.
    Wheler, J.
    Lipton, A.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2007, 22 (01): : 75 - 76
  • [2] Decline in serum HER-2/neu predicts response to trastuzumab-based therapy
    Leitzel, K.
    Esteva, F.
    Fornier, M.
    Gligorov, J.
    Harris, L.
    Kostler, W.
    Luftner, D.
    Pichon, M.
    Tse, C.
    Lipton, A.
    EJC SUPPLEMENTS, 2006, 4 (12): : 102 - 102
  • [3] Serum HER-2/neu decline predicts improved response to trastuzumab-based therapy in patients with normal and elevated baseline serum HER-2/neu levels.
    Ali, S. M.
    Brault, D.
    Brown-Shimer, S.
    Carney, W.
    Esteva, F. J.
    Fornier, M.
    Gligorov, J.
    Hamer, P.
    Harris, L.
    Leitzel, K.
    Kostler, W.
    Lotz, J-P
    Luftner, D.
    Pichon, M-F
    Thiel, R. P.
    Tse, C.
    Wheler, J.
    Lipton, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S90 - S90
  • [4] Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy.
    Ali, S. M.
    Esteva, F. J.
    Fornier, M.
    Gligorov, J.
    Harris, L.
    Kostler, W. J.
    Luftner, D.
    Pichon, M. F.
    Tse, C.
    Lipton, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 3S - 3S
  • [5] Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer
    Köstler, WJ
    Steger, GG
    Soleiman, A
    Schwab, B
    Singer, CF
    Tomek, S
    Brodowicz, T
    Krainer, M
    Wiltschke, C
    Horvat, R
    Jakesz, R
    Zielinski, CC
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1127 - 1130
  • [6] Monitoring therapy by serum HER-2/neu
    Schwartz, MK
    Smith, C
    Schwartz, DC
    Dnistrian, A
    Neiman, I
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2000, 15 (04): : 324 - 329
  • [7] Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
    Ali, Suhail M.
    Carney, Walter P.
    Esteva, Francisco J.
    Fornier, Monica
    Harris, Lyndsay
    Koestler, Wolfgang. J.
    Lotz, Jean-Pierre
    Luftner, Diana
    Pichon, Marie-France
    Lipton, Allan
    CANCER, 2008, 113 (06) : 1294 - 1301
  • [8] Automated assay for HER-2/neu in serum
    Payne, RC
    Allard, JW
    Anderson-Mauser, L
    Humphreys, JD
    Tenney, DY
    Morris, DL
    CLINICAL CHEMISTRY, 2000, 46 (02) : 175 - 182
  • [9] Serum HER2/neu change predicts clinical outcome to trastuzumab-based therapy
    不详
    ONCOLOGY-NEW YORK, 2006, 20 (09): : 1094 - +
  • [10] Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
    Mokhtari, Maral
    Khosravi, Mohammad Hadi
    MIDDLE EAST JOURNAL OF CANCER, 2021, 12 (04) : 483 - 490
12345